 I'm Bill Brough with a news update for the 2014 Genito-Uranary Cancer Symposium going on now in San Francisco. Argos Therapeutics Incorporated, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelus technology platform, announced that the company will present a trial in progress update on the company's ongoing Pivotal Phase 3 trial of AGS-003 for the treatment of metastatic renal cell carcinoma. That update will be presented in a poster session, Ongoing International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy, AGS-003, plus Standard Treatment and Advanced Renal Cell Carcinoma on Saturday, February 1st, during the general poster session at the Genito-Uranary Cancer Symposium. Reporting from San Francisco, I'm Bill Brough.